17 July 2018 in EMBO Reports
17 December 2018 in Nature Communications
Strict regulation of proliferation is vital for development, whereas unregulated cell proliferation is a fundamental characteristic of cancer. The polarity protein atypical protein kinase C lambda/iota (aPKCλ) is associated with cell proliferation through unknown mechanisms. In endothelial cells, suppression of aPKCλ impairs proliferation despite hyperactivated mitogenic signaling. Here we show that aPKCλ phosphorylates the DNA binding domain of forkhead box O1 (FoxO1) transcription factor, a gatekeeper of endothelial growth. Although mitogenic signaling excludes FoxO1 from the nucleus, consequently increasing c-Myc abundance and proliferation, aPKCλ controls c-Myc expression via FoxO1/miR-34c signaling without affecting its localization. We find this pathway is strongly activated in the malignant vascular sarcoma, angiosarcoma, and aPKC inhibition reduces c-Myc expression and proliferation of angiosarcoma cells. Moreover, FoxO1 phosphorylation at Ser218 and aPKC expression correlates with poor patient prognosis. Our findings may provide a potential therapeutic strategy for treatment of malignant cancers, like angiosarcoma.
15 September 2016 in Molecular Biology of the Cell
Blood vessel tubulogenesis requires the formation of stable cell-to-cell contacts and the establishment of apicobasal polarity of vascular endothelial cells. Cell polarity is regulated by highly conserved cell polarity protein complexes such as the Par3-aPKC-Par6 complex and the CRB3-Pals1-PATJ complex, which are expressed by many different cell types and regulate various aspects of cell polarity. Here we describe a functional interaction of VE-cadherin with the cell polarity protein Pals1. Pals1 directly interacts with VE-cadherin through a membrane-proximal motif in the cytoplasmic domain of VE-cadherin. VE-cadherin clusters Pals1 at cell–cell junctions. Mutating the Pals1-binding motif in VE-cadherin abrogates the ability of VE-cadherin to regulate apicobasal polarity and vascular lumen formation. In a similar way, deletion of the Par3-binding motif at the C-terminus of VE-cadherin impairs apicobasal polarity and vascular lumen formation. Our findings indicate that the biological activity of VE-cadherin in regulating endothelial polarity and vascular lumen formation is mediated through its interaction with the two cell polarity proteins Pals1 and Par3.
16 June 2021 in PLOS Computational Biology
Blood flow governs transport of oxygen and nutrients into tissues. Hypoxic tissues secrete VEGFs to promote angiogenesis during development and in tissue homeostasis. In contrast, tumors enhance pathologic angiogenesis during growth and metastasis, suggesting suppression of tumor angiogenesis could limit tumor growth. In line with these observations, various factors have been identified to control vessel formation in the last decades. However, their impacts on the vascular transport properties of oxygen remain elusive. Here, we take a computational approach to examine the effects of vascular branching on blood flow in the growing vasculature. First of all, we reconstruct a 3D vascular model from the 2D confocal images of the growing vasculature at postnatal day 5 (P5) mouse retina, then simulate blood flow in the vasculatures, which are obtained from the gene targeting mouse models causing hypo- or hyper-branching vascular formation. Interestingly, hyper-branching morphology attenuates effective blood flow at the angiogenic front, likely promoting tissue hypoxia. In contrast, vascular hypo-branching enhances blood supply at the angiogenic front of the growing vasculature. Oxygen supply by newly formed blood vessels improves local hypoxia and decreases VEGF expression at the angiogenic front during angiogenesis. Consistent with the simulation results indicating improved blood flow in the hypo-branching vasculature, VEGF expression around the angiogenic front is reduced in those mouse retinas. Conversely, VEGF expression is enhanced in the angiogenic front of hyper-branching vasculature. Our results indicate the importance of detailed flow analysis in evaluating the vascular transport properties of branching morphology of the blood vessels.
5 May 2025 in Advanced Functional Materials
Impaired vascular network remodeling is linked to tumor progression, impacting the efficacy of anti‐vascular therapies. However, the interplay between blood flow and vascular endothelial growth factor (VEGF) in driving vascular network remodeling remains unclear. This work optimizes a human vasculature‐on‐chip system for long‐term perfusion to quantify vascular network remodeling under physiologically low and tumor‐mimicking high VEGF conditions. Live imaging shows that at low VEGF levels, flow‐conditioned vascular networks remodel like animal models, enhancing flow velocities. Conversely, static networks lacking flow exhibit continuous growth, loss of network hierarchy, and decreased flow velocities. At tumor‐mimicking high VEGF levels, flow‐conditioned vessels show aberrant overgrowth, which is blocked by the anti‐VEGF tumor drug bevacizumab, restoring flow‐induced remodeling. Without flow, however, high VEGF slows vessel growth compared to low VEGF, while anti‐VEGF treatment restores continuous growth. These findings provide valuable insights into optimizing anti‐angiogenic therapies by exploiting VEGF modulation and flow conditions for vascular remodeling and improved tumor treatment.
1 June 2026 in Advanced Drug Delivery Reviews
The precise spatial organization of the heart across molecular, cellular, and tissue length scales underpins cardiac function. Recreating this architecture in engineered heart tissues remains a central challenge, as cardiac morphogenesis involves tightly coordinated, self-organizing programs governed by spatiotemporal biochemical, electrical, and mechanical cues. Although engineered cardiac systems have advanced substantially over the past two decades, most fail to recapitulate the dynamic spatial heterogeneity of the native myocardium. As a result, engineered constructs often exhibit immature phenotypes, impairing both tissue models and clinical applications. Here, we examine the principles and technologies that enable spatial control in cardiac tissue engineering. We first outline how spatial patterning arises in the native heart and distill design criteria relevant to engineered systems. Next, we summarize recent progress in the field including emerging applications of engineered heart tissues in organ-on-a-chip platforms and regenerative therapies. We then overview current approaches for guiding tissue organization, spanning biomolecular techniques that leverage morphogen gradients and multicellular signaling, electromechanical conditioning methods that promote cardiomyocyte alignment and maturation, and bioengineering platforms-including microfabrication, microfluidics, and bioprinting-that impose defined architectures and spatiotemporally controlled cues. We highlight how bottom-up self-organization and top-down engineering approaches are increasingly combined to generate hybrid systems that integrate user-defined structure with endogenous tissue assembly. Finally, we discuss the limitations of current-generation engineered tissues and speculate on future directions for the field, including adaptive and predictive design strategies. Collectively, these developments highlight spatial control as a central requirement for achieving the full capabilities of engineered cardiac tissues across basic and translational applications.